Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania. Show more

Location: One Commerce Square, Philadelphia, PA, 19103, United States | Website: https://www.passagebio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

22.65M

52 Wk Range

$5.12 - $26.60

Previous Close

$7.12

Open

$7.11

Volume

24,367

Day Range

$6.90 - $7.20

Enterprise Value

-10.25M

Cash

57.63M

Avg Qtr Burn

-9.017M

Insider Ownership

0.21%

Institutional Own.

54.51%

Qtr Updated

06/30/25